ARAV
- Aravive, Inc.
()
Overview
Company Summary
Aravive, Inc. (ARAV) is a biopharmaceutical company focused on developing innovative therapies for the treatment of severe diseases, specifically in the field of oncology and fibrosis. The company's main objective is to create novel therapies that target the fundamental mechanisms driving these diseases, providing new treatment options for patients.
Aravive's research and development efforts focus on developing therapeutic antibodies, which are proteins designed to specifically bind to certain molecules in the body and modulate their function. By targeting specific molecules involved in disease processes, the company aims to develop drugs that can effectively treat severe conditions with high unmet medical needs.
The flagship product of Aravive is AVB-500, a novel, potentially first-in-class treatment that targets the GAS6-AXL signaling pathway. This pathway is known to play a critical role in promoting tumor growth, metastasis, and treatment resistance in several types of cancer. AVB-500 works by binding to the AXL protein, suppressing its activity, and ultimately inhibiting the progression of cancerous cells.
Additionally, Aravive explores opportunities to utilize AVB-500 in other disease indications with fibrosis, such as idiopathic pulmonary fibrosis (IPF) and kidney fibrosis. By targeting fibrotic processes, the company aims to develop therapies that can halt or reverse tissue scarring and organ damage caused by these conditions.
As a biopharmaceutical company, Aravive also collaborates with research institutions, pharmaceutical companies, and regulatory authorities to advance its drug candidates through pre-clinical and clinical development stages. The ultimate goal is to obtain regulatory approvals and bring these innovative therapies to patients worldwide, improving their quality of life and addressing significant unmet medical needs.